cytomegalovirus-specific t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02702427)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cytomegalovirus-specific t-cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06157541 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2024 | Merck, University of Melbourne, University of Queensland, University of Sydney |
| NCT02702427 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | St. Anna Kinderkrebsforschung |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 0 | 1 | 2024 |
| St. Anna Kinderkrebsforschung | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Melbourne | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Queensland | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1